MiNK Therapeutics, Inc. (NASDAQ:INKT)
| Market Cap | $41.17M-24.1% |
| Revenue (ttm) | $200.00K |
| Net Income | -$11.02M+10.8% |
| EPS | -$2.24+26.8% |
| Shares Out | 5.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,030 |
| Open | $8.32 |
| Previous Close | $8.61 |
| Day's Range | $7.76 - $8.60 |
| 52-Week Range | $7.76 - $16.93 |
| Beta | 0.45 |
| Analysts | Buy |
| Price Target | $35.00(+336.41%) |
| Earnings Date | Mar 23, 2027 |
About INKT
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating INKT in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 23, 2027Earnings report
$INKT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in INKT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by INKT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
INKT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New INKT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to INKT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in INKT
| VTIVanguard Morningstar Total Stock Market ETF | $440.36K |
| VXFVanguard Extended Market ETF | $161.97K |
| IWCiShares Micro-Cap ETF | $52.74K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from INKT’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 revenue beats, first commercial product revenue, ARDS trial advancement, and ARPA-H selection demonstrate meaningful clinical and commercial progress.
